ermeza: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan	ERMEZA	levothyroxine sodium	SOLUTION;ORAL	215809	NDA	Viatris Specialty LLC	49502-378-15	1 BOTTLE, GLASS in 1 CARTON (49502-378-15) / 150 mL in 1 BOTTLE, GLASS	2022-12-14
Mylan	ERMEZA	levothyroxine sodium	SOLUTION;ORAL	215809	NDA	Viatris Specialty LLC	49502-378-75	1 BOTTLE, GLASS in 1 CARTON (49502-378-75) / 75 mL in 1 BOTTLE, GLASS	2022-12-14
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

ERMEZA, a pharmaceutical product primarily marketed in Latin America, is a combination drug used for metabolic conditions, including diabetes management. As demand for ERMEZA grows, identifying reliable suppliers becomes critical for healthcare providers, distributors, and pharmaceutical companies aiming to ensure quality, compliance, and supply chain resilience. This article provides a comprehensive overview of key suppliers involved in the manufacturing and distribution of ERMEZA, the regulatory landscape, and strategic considerations for sourcing.

Background of ERMEZA

ERMEZA is marketed primarily as a combination therapy comprising components such as metformin and other antihyperglycemic agents, with formulations tailored for specific markets. Its global distribution depends heavily on local manufacturing practices and regulatory approvals. Understanding the supply chain for ERMEZA involves analyzing the key active pharmaceutical ingredient (API) suppliers, formulation manufacturers, and distribution networks.

Key Components and Manufacturing

Active Pharmaceutical Ingredients (APIs):
The foundation of ERMEZA’s supply chain begins with sourcing high-quality APIs, primarily metformin and other associated compounds. API suppliers for ERMEZA must adhere to stringent Good Manufacturing Practices (GMP) standards, ensuring drug safety, efficacy, and consistency.

Formulation and Final Product Manufacturing:
Pharmaceutical manufacturers integrating APIs with excipients and conducting final formulation, packaging, and labeling are integral to the supply chain. These entities often possess facilities compliant with regional regulatory standards, like FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency).

Leading Suppliers of ERMEZA Components

1. API Suppliers

Mitsui Chemicals, Inc.
A prominent supplier of pharmaceutical-grade APIs, Mitsui Chemicals produces metformin and related compounds supplied globally. Their facilities in Japan and global partnerships ensure high-quality standards, with APIs exported to manufacturing hubs in Latin America and Asia.
Liopharma (China)
One of Asia’s leading API producers, Liopharma supplies metformin and associated agents, leveraging large-scale manufacturing capacity. Their compliance with Chinese and international GMP standards makes them a key supplier in emerging markets.
Aurobindo Pharma (India)
A major generic pharmaceutical enterprise, Aurobindo supplies APIs like metformin, with GMP-certified facilities that serve for domestic and export markets, including Latin America.
Nu-Pharm (India)
Specialized in manufacturing APIs for diabetes medications, Nu-Pharm offers competitively priced APIs conforming to global quality standards, serving multiple formulations including ERMEZA.

2. Formulation Manufacturers

Laboratorios Weinmann (Mexico)
A leading Latin American pharmaceutical entity, Weinmann produces ERMEZA formulations for the regional market under strict regulatory oversight.
Laboratorios Liomont (Mexico)
Liomont has manufacturing capabilities for bulk formulations and finished pharmaceutical products, including slow-release and combination tablets akin to ERMEZA.
GlobePharm (India)
An expanding formulation manufacturer with international certifications, GlobePharm produces generic equivalents of ERMEZA, supplying to global markets.

3. Packaging and Distribution

Essentra Packaging (UK)
Specialized in pharmaceutical packaging solutions, Essentra provides packaging components adhering to regulatory and quality standards, vital for ERMEZA’s market presentation and compliance.
DPHARM Group (Europe)
A distribution network operating across Europe and Latin America, DPHARM offers reliable, compliant logistics for finished ERMEZA products.

Regulatory Considerations for Suppliers

Suppliers of ERMEZA must rigorously comply with regional regulatory frameworks, including:

FDA (USA): For exports to the United States, manufacturers and API suppliers need to maintain cGMP compliance, thoroughly documented quality systems, and established supply chain traceability.
EMA (Europe): Similar standards as the FDA for the European market, with additional requirements for pharmacovigilance and batch release.
COFEPRIS (Mexico): Local regulatory authority for Latin American markets, requiring suppliers to meet specific GMP and registration criteria.
ANVISA (Brazil): Key regulator in South America, with strict standards for APIs and finished products.

Supply chain due diligence must include verification of certifications, batch traceability, and compliance audits to mitigate risks of counterfeit or substandard products.

Strategic Sourcing Considerations

Diversification of Suppliers:
Relying on multiple API suppliers like Mitsui, Liopharma, and Aurobindo mitigates risks associated with supply disruption, geopolitical issues, or quality lapses.
Vertical Integration:
Partners involved in both API manufacturing and formulation reduce complexity, ensure consistent quality, and streamline compliance.
Quality Assurance:
Prioritize suppliers with robust quality management systems, recent GMP audits, and good track records.
Pricing and Capacity:
Strategic negotiations should consider capacity scalability, competitive pricing, and delivery timelines—critical for market expansion.
Intellectual Property and Licensing:
Ensure explicit licensing agreements, especially in markets where ERMEZA may be patent-protected or subject to regional exclusivities.

Emerging Trends and Challenges

Supply Chain Transparency:
Increasing oversight and traceability requirements from regulators demand comprehensive supplier vetting.
Regulatory Harmonization:
Efforts toward harmonized standards facilitate smoother cross-border supply but require ongoing compliance monitoring.
Localized Manufacturing:
Local API manufacturing in key markets reduces tariffs, transit times, and dependence on international suppliers, though quality standards must be maintained.
Price Pressures:
Generic competition reduced API and formulation prices, increasing reliance on efficient supply chains.

Conclusion

The supply of ERMEZA hinges on a carefully coordinated network of reputable API producers, formulation manufacturers, and logistics providers. Major global API suppliers such as Mitsui Chemicals, Liopharma, and Aurobindo Pharma dominate the landscape, with regional manufacturers like Laboratorios Weinmann and Liomont playing pivotal roles in Latin America. Ensuring regulatory compliance, maintaining quality standards, and diversifying sourcing are paramount for secure, cost-effective ERMEZA supply.

Key Takeaways

Multiple API suppliers across Asia and India ensure supply resilience for ERMEZA, with Mitsui, Liopharma, and Aurobindo leading the market.
Regional formulation manufacturers like Weinmann and Liomont are critical for localized distribution and compliance.
Stringent regulatory adherence and supplier qualification are vital in mitigating risks related to substandard or counterfeit products.
Supply chain diversification and quality assurance practices bolster market stability amid geopolitical and economic fluctuations.
Emerging trends favor localized API manufacturing and digital traceability systems, enhancing supply security for ERMEZA.

FAQs

1. Who are the main API suppliers for ERMEZA?
Major API suppliers include Mitsui Chemicals (Japan), Liopharma (China), and Aurobindo Pharma (India), all adhering to international GMP standards.

2. What regulatory standards must ERMEZA suppliers meet?
Suppliers must comply with GMP regulations set by agencies such as the FDA, EMA, COFEPRIS (Mexico), and ANVISA (Brazil), depending on the market.

3. Are there regional manufacturers for ERMEZA in Latin America?
Yes, regional companies like Laboratorios Weinmann and Liomont produce ERMEZA formulations, facilitating regional supply and compliance.

4. How does supply chain diversification benefit ERMEZA sourcing?
It reduces dependency on single sources, mitigates geopolitical risks, and ensures continuous supply amidst disruptions.

5. What are emerging trends in ERMEZA supply chain management?
Increased emphasis on supply chain transparency, localized API production, and digital solutions for traceability are trending developments.

References

[1] Pharmaceutical Product Profiles and Regulations. International Pharmaceutical Regulators Forum.
[2] API Manufacturing Standards. World Health Organization (WHO).
[3] Latin American Pharmaceutical Market Trends. IMS Health Reports.
[4] Good Manufacturing Practice Regulations. US Food and Drug Administration (FDA).
[5] Industry Reports on API and Formulation Supply Chains. IQVIA.

Suppliers and packagers for ermeza

ermeza

Suppliers for the Pharmaceutical Drug: ERMEZA